{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:26:17Z","timestamp":1783023977884,"version":"3.54.6"},"reference-count":6,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>\n                    Immunoreactive encephalitis is a very rare side effect of immunotherapy, which can lead to severe morbidity. Following azetolizumab, it typically occurs within 0\u201312 months, with a median of 15 days. In this case, immunoreactive encephalitis occurred 3.5 months after treatment with azetolizumab ended and 15.5 months after it began. Tumefactive demyelinating lesions represent a focal cerebral lesion with inflammatory demyelination. They are usually associated with multiple sclerosis, but can also occur drug-induced or in the context of autoantibody-mediated diseases. In MRI, tumefactive demyelinating lesions mimic cerebral metastases.\n                    <jats:sup>18<\/jats:sup>\n                    F-FDG PET\/CT can enhance the diagnostic precision of both immunoreactive encephalitis and tumefactive demyelinating lesions.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000006535","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:01:57Z","timestamp":1781647317000},"page":"654-656","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Synchronous Late-Onset of Limbic Encephalitis and Tumefactive Demyelinating Lesion After the End of Immunotherapy"],"prefix":"10.1097","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1344-6410","authenticated-orcid":false,"given":"Marcel","family":"Baehr","sequence":"first","affiliation":[{"name":"Radiology, Neuroradiology, and Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter D.","family":"Schellinger","sequence":"additional","affiliation":[{"name":"Neurology and Neurogeriatrics, Ruhr University Bochum, Johannes Wesling Hospital Minden, Minden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Borggrefe","sequence":"additional","affiliation":[{"name":"Radiology, Neuroradiology, and Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Surov","sequence":"additional","affiliation":[{"name":"Radiology, Neuroradiology, and Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"R1-20260702","doi-asserted-by":"crossref","first-page":"oyae186","DOI":"10.1093\/oncolo\/oyae186","article-title":"Immune-related encephalitis after immune checkpoint inhibitor therapy","volume":"30","author":"Buckley","year":"2025","journal-title":"Oncologist"},{"key":"R2-20260702","doi-asserted-by":"crossref","first-page":"42218","DOI":"10.1038\/s41598-025-26340-2","article-title":"Post marketing safety surveillance of atezolizumab based on a retrospective analysis of the FDA Adverse Events Reporting System (FAERS)","volume":"15","author":"Zhang","year":"2025","journal-title":"Sci Rep"},{"issue":"15","key":"R3-20260702","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.3390\/cancers17152461","article-title":"Late-Onset Immune-Related Adverse Events in Patients with Advanced Melanoma: The LATENT Study.","volume":"17","author":"Pozas","year":"2025","journal-title":"Cancers (Basel)"},{"key":"R4-20260702","doi-asserted-by":"crossref","first-page":"11795735251340051","DOI":"10.1177\/11795735251340051","article-title":"Paraneoplastic tumefactive demyelination with underlying anaplastic thyroid cancer: a case report and review of the literature","volume":"17","author":"Panagiotis","year":"2025","journal-title":"J Cent Nerv Syst Dis"},{"key":"R5-20260702","doi-asserted-by":"crossref","first-page":"868525","DOI":"10.3389\/fneur.2022.868525","article-title":"Immunopathology of tumefactive demyelinating lesions-from idiopathic to drug-related cases","volume":"13","author":"Vakrakou","year":"2022","journal-title":"Front Neurol"},{"key":"R6-20260702","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1158\/2326-6066.CIR-15-0141","article-title":"Subacute CNS demyelination after treatment with nivolumab for melanoma","volume":"3","author":"Maurice","year":"2015","journal-title":"Cancer Immunol Res"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006535","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:03:44Z","timestamp":1783022624000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":6,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006535","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"2026-04-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}